KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.70

Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study).

Tsutomu Kobayashi, Kenichi Ishizawa, Ryunosuke Machida, Ryo Sadachi, Keita Sasaki, Haryoon Kim, Keisuke Kataoka, Wataru Munakata, Noriko Fukuhara, Hirokazu Nagai, Lymphoma Study Group of the Japan Clinical Oncology Group

Jpn J Clin Oncol 55(6) 666-671

PMID39997358
PMCIDPMC12138771
DOI10.1093/jjco/hyaf038
发表日期2025-02-25
入排依据:The record describes a randomized Phase III trial for follicular lymphoma with drug interventions (obinutuzumab, bendamustine), but the abstract is a protocol/study description without reporting any efficacy results, including time-to-event endpoints (OS, PFS, etc.) or Kaplan-Meier/HR data. It lacks the required primary or secondary time-to-event efficacy endpoint report.
已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram。
摘要

摘要

Maintenance therapy with monoclonal anti-CD20 antibody is the standard approach in patients with follicular lymphoma who initially treated and achieved response to immunochemotherapy. Maintenance therapy reduces the risk of lymphoma progression, but the risk of late or delayed fatal treatment-emergent adverse events is a clinically important issue. The aim of this randomized phase III study is to confirm the non-inferiority of observation compared to obinutuzumab maintenance therapy in patients with untreated high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy (JCOG2008, MAIN study). The first registration is performed before obinutuzumab plus bendamustine administration. Those who achieved complete metabolic response at the end of induction are included in the second registration and randomized to an obinutuzumab maintenance arm or observation only. This study has been registered in the Japan Registry for Clinical Trials as jRCT1031210379.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Study schema of JCOG2008. ECOG PS, European Clinical Oncology Group Performance Status; FLIPI2, follicular lymphoma international prognostic index 2.
非 KM Figure